TransCode Therapeutics Advances Clinical Development of TTX-MC138
Recently, TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a company at the forefront of immuno-oncology and RNA therapeutics, revealed an essential milestone in its clinical development program. Collaborating with Quantum Leap Healthcare Collaborative, TransCode has submitted an amendment for an Investigational New Drug (IND) application to the FDA. This amendment is intended for a planned Phase 2a clinical trial featuring the lead therapeutic candidate, TTX-MC138.
Overview of the Phase 2a Clinical Trial
The upcoming study is set to take place under the auspices of the PRE-I-SPY program, a pioneering platform designed to facilitate innovative oncology clinical trials. Noteworthily, this will mark the first time the program expands its focus to include colorectal cancer. The Phase 2a trial will aim to enroll up to 45 patients diagnosed with colorectal cancer who have successfully undergone standard curative-intent therapy and exhibit positive circulating tumor DNA (ctDNA) markers.
Significance of Circulating Tumor DNA in Cancer Treatment
Emerging research highlights ctDNA as a promising prognostic indicator for identifying patients at risk of cancer recurrence. This attribute allows for the potential detection of minimal residual disease (MRD), which may be responsive to timely therapeutic interventions. TransCode's Phase 2a trial aims to explore the biological and clinical activity of TTX-MC138 in patients identified with MRD, where therapeutic opportunities are anticipated to yield substantial long-term benefits.
Leadership and Collaboration in Clinical Research
The trial will be spearheaded by Dr. Paula Pohlmann from the renowned MD Anderson Cancer Center. TransCode's Senior VP, Operations, Sue Duggan, expressed enthusiasm regarding this IND submission, describing it as a transformative step within the clinical development program. According to Duggan, the collaboration with Quantum Leap’s PRE-I-SPY program enables the exploration of TTX-MC138, advancing its integration into new treatment horizons.
Joining Forces with the Colorectal Cancer Alliance
Furthermore, the clinical trial will unfold across various clinical sites belonging to the PRE-I-SPY Platform Network, which includes numerous participants from the National Cancer Center Network. The program also echoes a commitment to collaboration with the Colorectal Cancer Alliance, a preeminent advocacy organization devoted to improving the lives of those impacted by colorectal cancer. Further details regarding the PRE-I-SPY program and the accompanying Phase 2a trial can be accessed on clinicaltrials.gov.
About TransCode Therapeutics
TransCode Therapeutics is dedicated to pioneering advancements in immuno-oncology and RNA therapeutics aimed at addressing advanced cancers. The company’s flagship candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, an established biomarker linked to cancer metastasis. In addition to its primary candidate, TransCode offers a robust lineup of first-in-class therapeutic options designed to harness the immune system's potential to recognize and eradicate cancer cells.
Conclusion and Future Prospects
The impending clinical trial reflects TransCode Therapeutics’ unwavering commitment to advancing its clinical research endeavors. As the study initiates, the company anticipates valuable insights that could significantly improve treatment strategies for colorectal cancer patients and broader oncology applications.
Frequently Asked Questions
What is the focus of TransCode's Phase 2a clinical trial?
The Phase 2a clinical trial aims to evaluate TTX-MC138's efficacy in colorectal cancer patients, particularly those with positive markers for circulating tumor DNA.
Who is leading the clinical trial?
The trial is led by Dr. Paula Pohlmann of MD Anderson Cancer Center, a key institution in cancer research.
How many patients will be involved in the trial?
Up to 45 patients with colorectal cancer are expected to participate in the Phase 2a trial.
What role does Quantum Leap play in this collaboration?
Quantum Leap Healthcare Collaborative is partnering with TransCode to conduct the clinical trial under the PRE-I-SPY program.
What target does TTX-MC138 focus on?
TTX-MC138 targets metastatic tumors that overexpress microRNA-10b, which is associated with cancer metastasis.
